TS-076401 — Many progressive diseases, including cardiac, neurological, and other chronic disorders, begin with subtle molecular and cellular changes long before conventional clinical signs become detectable. Current diagnostic approaches generally identify disease only after significant tissue remodeling or …

TS-076286 — Literature shows that Negative Pressure Wound Therapy (NPWT) combined with fluid instillation can improve abdominal trauma patient outcomes. Current standards of practice are inefficient, involving assembly and off-label use of at least 8 medical products. This is further complicated by varied pro…

TS-075261 — Problem Hemolysis, the process by which the red blood cell membrane ruptures, releasing hemoglobin (Hb), is typically managed in mammalian organisms by intrinsic proteins such as hemopexin (Hpx) and haptoglobin (Hp). However, their concentrations in plasma are very limited, so, in conditions with s…

TS-075238 — Problem Low titer group O whole blood (LTOWB) is the gold standard used by the US military to treat blood loss. However, there is a limited supply with ex vivo storage and shelf-life limitations. There is no whole blood substitute on the market when LTOWB is not available. Solution Dr. Andre Palmer and team have developed several whole blood substitute formulations to mimic the 3 main functions of whole blood: 1) oxygen transport (provided by hemoglobin-based oxygen carrier [HBOC]); 2) clotting (provided by tranexamic acid); and 3) volume replacement (provided by a plasma substitute). The HBOC consists of T-state polymerized human hemoglobin (PolyhHb). The clotting agent consists of tranexamic acid (TXA). The volume replacement solution consists of polymerized human serum albumin (PolyHSA). Additional additives include high molecular weight polyethylene glycol as a drag reducing agent, and dexamethasone as an anti-inflammatory agent. Applications Prehospital and austere environments Used by EMS and military for early resuscitation before hospital arrival Hospital trauma protocols Used for first-line transfusion in exsanguinating patients Advantages Mimics the three major functions of whole blood without the risk of blood type incompatibility and disease transmission Extended shelf life versus whole blood Scalable production Seeking opportunities for out-licensing and collaboration

TS-075185 — Problem The lipolysis-stimulated lipoprotein receptor (LSR) is a promising target for cancer therapy. LSR is overexpressed in many tumor tissues with metastatic signatures such as breast, gastric, and endometrial cancer. LSR expression levels may serve as prognostic indicators and help stratify pat…

TS-075179 — Problem Mitochondria is a promising target for cancer treatment. However, current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited. Solution Applications Competitive Advantages Seeking Opportunities for Licensing and collaboration

TS-075177 — Problem Glioblastoma multiforme (GBM) is the most malignant form of gliomas and the most lethal primary brain tumors in adults. Current biomarkers or clinical features from tissue biopsy samples cannot distinguish glioma true progression from pseudoprogression and might not be suited to monitoring …

TS-075165 — Problem Neuroendocrine tumors (NETs) are often metastatic at diagnosis, thus limiting surgical options. Chemotherapies offer limited efficacy and high toxicity. Meningiomas, though usually benign, are the most common intracranial tumors. Both NETs and meningiomas overexpress SSTR2, making it a prom…

TS-074779 — Myopia is rapidly increasing worldwide and is now recognized as a leading cause of irreversible vision impairment due to associated complications such as retinal degeneration, glaucoma, and structural eye changes. Despite this growing burden, clinicians lack practical tools to assess structural ch…

TS-074767 — Chronic and complex wounds remain a major clinical and economic burden, with high infection rates, slow healing trajectories, and limited real-time monitoring capabilities. Conventional dressings are largely passive and do not adapt to dynamic wound environments, while existing advanced therapies …

TS-073584 — Endotoxins from gram‑negative bacteria pose serious risks in pharmaceutical manufacturing, medical devices, food, and water systems, even at picogram-per-milliliter levels. Current standard methods, such as the LAL assay, require specialized reagents, laboratory infrastructure, and raise cost, s…

TS-073320 — Current methods for engineering micro- and nanoscale surface topographies on elastomeric materials are often costly, complex, and incompatible with scalable manufacturing. Yet, surface microstructures are critical for enhancing biological interactions in wound healing materials, such as promoting …

TS-073264 — Low‑oxygen, toxic environments created by fires or explosions in mines, tunnels, and enclosed spaces remain a leading cause of fatalities for trapped occupants and rescuers. Current self‑contained breathing and escape devices are constrained by limited oxygen supply, bulk, weight, heat generat…

TS-070304 — The Need Current clinical methods for assessing tremor severity in patients with Parkinson’s disease and other movement disorders rely heavily on subjective, qualitative observations, such as evaluating hand-drawn spirals or observing motor tasks. These approaches lack precision, are difficult…

TS-069527 — The Need Cardiovascular MRI (CMR) data acquisition is often time-consuming and relies on complex reconstruction methods that do not fully exploit the spatial and temporal structure of CMR data. There is a need for a more efficient, unsupervised approach that can accelerate CMR imaging while maintai…

TS-067796 — A handheld device for identifying preterm blood vessels in neonatal ICU.

TS-066962 — The Need Viral disease surveillance (e.g. influenza, SARS-CoV-2) in high-risk settings faces several challenges, such as asymptomatic carriers, incomplete reporting, resource limitations, and delayed diagnosis of traditional swab test methods. These challenges could allow a virus to silently spread…

TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-065684 — Non-viral gene therapy for minimally invasively treating painful musculoskeletal disorders

TS-064046 — Dermal substitute with engineered rete ridges improves epidermal-dermal communication and enhances burn wound treatment.

TS-063959 — The Need Millions of individuals suffer from constipation due to the inability to relax pelvic floor muscles during bowel movements, leading to discomfort and strained efforts. Current solutions, like the Squatty Potty, lack adjustability and portability, limiting their effectiveness for a diverse …

TS-063919 — An articulating end effector for additive manufacturing that utilizes robot-assisted endoscopic surgery to implant synthetic tissues at local defects through “keyhole” incisions in patients. This innovative technology T2019-145 is part of a portfolio that also includes T2017-363. To learn more about both technologies, please visit https://oied.osu.edu/find-technologies and search using the phrase: Endoscopic additive manufacturing of biomaterials.

TS-063433 — A new pharmacologic modality for treating AFib.

TS-063154 — Worldwide, 686,000 new head and neck (H&N) cancers are diagnosed yearly, and 375,000 people will die annually. Human papillomavirus (HPV) is responsible for an increasing subset of H&N malignancies called oropharyngeal squamous cell carcinomas (OPSCC). Although it has a better prognosis than…

TS-063069 — In the wake of the global pandemic caused by SARS-CoV-2, the need for rapid, accurate, and efficient diagnostic methods for respiratory viral infections has become more critical than ever. Traditional diagnostic methods, while reliable, are often time-consuming, labor-intensive, and lack the neces…

TS-062900 — This cutting-edge technology redefines the intubation process by guiding the endotracheal tube into the airway with exceptional precision.

TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications

TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.

TS-062505 — The Need Glaucoma and myopia are significant causes of vision loss worldwide, affecting millions of people and imposing a substantial socioeconomical burden. Effective vision care strategies are urgently needed to reduce blindness caused by these conditions and mitigate their associated risks. In v…

TS-062497 — The Need: The field of ophthalmology requires advanced diagnostic tools to effectively diagnose, prevent, and treat various eye conditions. While ultrasound imaging is well-known in fields like pregnancy check-ups and vascular imaging, its potential in ophthalmology remains largely untapped. There …

TS-061547 — A venous access port device that leverages near-field communication (NFC) to automate needle placement as well as a disposable needle cartridge to increase the ease of and help maintain aseptic access to the port.

TS-060782 — Problem Statement: Diagnosis of arterial occlusion and an associated stroke can be lengthy, delaying patient access to treatment. As large vessel occlusions account for 24 to 46% of acute ischemic strokes and may require treatment in a comprehensive stroke center, early diagnosis is key. Solution:…

TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.

TS-054464 — Novel drug delivery system that enables efficient transfer of FDA-approved drugs for the treatment of neurological injuries.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute

TS-043186 — A novel acoustic/ultrasonic wave-energy guiding system that utilizes structural topology to enhance directional and spectral sensitivities instead of phase delay, offering exceptional versatility and adaptable performance.

TS-038384 — A novel device for monitoring cancer cell motility in real time using standard microscopy.

TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.

TS-038028 — Transcatheter heart valve (THV) with novel leaflet materials and design profile that results in reduced thrombogenicity, improved durability, and lower manufacturing cost